1.54
price up icon2.67%   0.04
after-market Handel nachbörslich: 1.53 -0.01 -0.65%
loading
Schlusskurs vom Vortag:
$1.50
Offen:
$1.52
24-Stunden-Volumen:
140.64K
Relative Volume:
0.79
Marktkapitalisierung:
$36.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.76M
KGV:
-1.6559
EPS:
-0.93
Netto-Cashflow:
-
1W Leistung:
+1.32%
1M Leistung:
+58.76%
6M Leistung:
+57.13%
1J Leistung:
+42.59%
1-Tages-Spanne:
Value
$1.44
$1.57
1-Wochen-Bereich:
Value
$1.44
$1.6472
52-Wochen-Spanne:
Value
$0.512
$1.6472

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name
Firmenname
Neurosense Therapeutics Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
NRSN's Discussions on Twitter

Vergleichen Sie NRSN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NRSN
Neurosense Therapeutics Ltd
1.54 36.46M 0 -13.76M 0 -0.93
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten

pulisher
May 20, 2025

NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia

May 20, 2025
pulisher
May 14, 2025

D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World

May 14, 2025
pulisher
May 13, 2025

D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga

May 12, 2025
pulisher
May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com

May 12, 2025
pulisher
May 07, 2025

NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks

May 07, 2025
pulisher
May 07, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq

May 07, 2025
pulisher
May 06, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN

May 06, 2025
pulisher
May 05, 2025

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN

May 05, 2025
pulisher
Apr 30, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World

Apr 30, 2025
pulisher
Apr 24, 2025

NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow

Apr 24, 2025
pulisher
Apr 23, 2025

Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World

Apr 23, 2025
pulisher
Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025
pulisher
Apr 09, 2025

Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan

Apr 09, 2025
pulisher
Apr 09, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire

Apr 09, 2025
pulisher
Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN

Apr 08, 2025
pulisher
Apr 07, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - The Malaysian Reserve

Apr 07, 2025
pulisher
Apr 04, 2025

NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PR Newswire

Apr 04, 2025
pulisher
Mar 31, 2025

Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com

Mar 31, 2025
pulisher
Mar 27, 2025

NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire

Mar 24, 2025
pulisher
Mar 24, 2025

Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com

Mar 24, 2025
pulisher
Mar 22, 2025

NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge

Mar 21, 2025
pulisher
Mar 20, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

NeuroSense Advances PrimeC Commercialization in Canada - TipRanks

Mar 19, 2025
pulisher
Mar 17, 2025

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan

Mar 17, 2025
pulisher
Feb 27, 2025

The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury

Feb 27, 2025
pulisher
Feb 19, 2025

NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks

Feb 19, 2025

Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):